Type 2 & other diabetes

Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes

Diabetes Technol TherPublished Single-arm interventional study

Authors' conclusion

These findings show that MiniMed 780G AHCL use provides safe insulin intensification in type 2 diabetes and significantly improves mean HbA1c and %TIR.

Study context

Population
Adults with insulin-requiring T2D using basal-bolus insulin therapy; mean age 60.3 ± 10.8 years, T2D duration 18.6 ± 8.6 years
Participants
95 adults
Comparison
MiniMed 780G advanced hybrid closed-loop (AHCL) vs baseline/run-in
  • AHCLn = 95
Outcome
Primary safety end point: mean change in HbA1c from baseline; primary effectiveness end point: noninferiority in %TIR 70-180 mg/dL (Hodges-Lehmann)
Follow-up
End of 3-month study period; %TIR during last 6 weeks
Methodological details13-site, open-label
  • 13-site
  • Open-label

Main finding

As reported in the abstract

end of 3-month study period
HbA1c at baseline
7.9% ± 1.0% (62.4 ± 10.4 mmol/mol)
HbA1c at end of study
7.2 ± 0.7% (54.7 ± 8.0 mmol/mol)
HbA1c reduction
P < 0.001
%TIR estimate (last 6 weeks)
80.9% (95% CI 78.4%, 83.1%)
Primary (noninferiority) and secondary (superiority) effectiveness criteria met
P < 0.001

Further findings

Total daily insulin dose · run-in to end of study

Run-in vs end of study
77.4 ± 38.5 U vs. 91.8 ± 49.3 U, P < 0.0001

Daily user-initiated boluses · run-in to end of study

Run-in vs end of study
3.9 ± 1.9 vs. 3.2 ± 1.8, P < 0.0001

Announced carbohydrates, weight and BMI

Announced carbohydrates unchanged; no significant change in weight or BMI

Safety

Severe hypoglycemia, diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS)
0
Serious or unanticipated adverse device effects
0

Original publication

Safety and Effectiveness of MiniMed TM 780G Advanced Hybrid Closed-Loop Insulin Intensification in Adults with Insulin-Requiring Type 2 Diabetes. Diabetes Technol Ther. Published 6 February 2025. doi:10.1089/dia.2024.0586

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.